



ASX Announcement
23 January 2019

Elixinol product launches in New Zealand market following change in legislation

HIGHLIGHTS:

- **Elixinol branded products now available to patients in New Zealand market, with first prescription successfully shipped**
- **The launch follows the passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which classifies CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug**
- **Full range of Elixinol branded capsules, topicals, and tinctures including liposomes meet the required standard for import to New Zealand**

Elixinol Global Limited (EXL, Group or the Company) (ASX:EXL; OTCQX:ELLXF), a global company operating in the hemp, dietary supplements and emerging medicinal cannabis sectors, is pleased to announce that Elixinol branded cannabidiol (CBD) products are now available on a prescription basis in the New Zealand market via the www.elixinol.com e-commerce website.

The launch follows the passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which classifies CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug.

Under the Act, which recognizes CBD as a substance with “therapeutic value with little or no psychoactive properties”, individual patients may now import up to a three-month supply of CBD products, provided those products meet prescription medicine guidelines. Patients in New Zealand can also enter or leave New Zealand with up to three months’ supply of CBD with evidence of prescription.

Elixinol branded capsules, topicals, and tinctures including liposomes meet the required standard for import into New Zealand. Elixinol has already started to receive prescriptions and is happy to announce the first shipment has now been successfully received in New Zealand.

Paul Benhaim, CEO of parent company EXL, commented, “Over the past few weeks, we have seen a groundswell of change in legislation related to cannabidiol. The US Farm Bill was passed in December, and through that process, CBD was de-scheduled from the Controlled Substances Act. Now, this change in New Zealand enables Elixinol to ship CBD to patients who have been requesting it for years. We are delighted to be one of the first companies to supply New Zealand patients with the range our US customers have been benefiting from for years”.



Customers with valid prescriptions in New Zealand should contact Elixinol through the website www.elixinol.com

###

Investor relations and media please contact:

Australia

Glen Zurcher

Account Director, IR Department

IR@elixinolglobal.com

+61 420 249 299

United States of America

Cody Slach

Managing Director, Liolios Group Inc

USIR@elixinolglobal.com

+1 949 574 3860

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) through its businesses has a global presence in the cannabis industry including hemp CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. Elixinol Global's businesses include:

- Elixinol, which was founded in 2014, is a manufacturer and global distributor of hemp dietary supplement and skincare products, with operations based out of Colorado, USA;
- Hemp Foods Australia, which was founded in 1999, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products;
- Elixinol Australia, was founded in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.

See more at www.elixinolglobal.com